Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC

Park Avenue Securities LLC lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,358 shares of the biotechnology company’s stock after purchasing an additional 707 shares during the period. Park Avenue Securities LLC’s holdings in Exelixis were worth $272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EXEL. Vanguard Group Inc. increased its stake in Exelixis by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after purchasing an additional 121,750 shares during the last quarter. LSV Asset Management raised its holdings in Exelixis by 0.8% during the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock worth $272,056,000 after buying an additional 67,470 shares during the period. Fuller & Thaler Asset Management Inc. raised its holdings in Exelixis by 10.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock worth $254,110,000 after buying an additional 708,312 shares during the period. Invesco Ltd. increased its holdings in shares of Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after purchasing an additional 3,001,204 shares during the period. Finally, AQR Capital Management LLC increased its holdings in shares of Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock valued at $132,101,000 after purchasing an additional 810,857 shares during the period. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

EXEL has been the topic of a number of research reports. Morgan Stanley restated an “overweight” rating and issued a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. HC Wainwright increased their price objective on Exelixis from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim set a $45.00 price objective on Exelixis and gave the company a “buy” rating in a research report on Thursday, May 15th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 target price on shares of Exelixis in a research note on Wednesday, May 14th. Finally, UBS Group reiterated an “underperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.76.

Insiders Place Their Bets

In related news, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director now owns 358,882 shares of the company’s stock, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the sale, the executive vice president now directly owns 693,181 shares in the company, valued at approximately $27,034,059. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,113 shares of company stock worth $21,024,817. Insiders own 2.82% of the company’s stock.

Exelixis Stock Down 0.5%

Exelixis stock opened at $41.59 on Monday. The business’s 50-day simple moving average is $39.69 and its 200 day simple moving average is $36.88. The stock has a market cap of $11.34 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 12-month low of $21.36 and a 12-month high of $48.85.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.